Anocca

Anocca is a biotechnology startup based in Sweden, founded in 2014, with the slogan "Engineered Immunity." The company specializes in T-cell biology and has developed a unique technology platform to replicate functional human cellular immunobiology, unlocking the potential of T-cell immunotherapies and vaccine strategies. Anocca's proprietary technologies enable the efficient and precise harnessing and manipulation of T-cell immunity, paving the way for next-generation therapies and vaccination strategies in oncology, infectious diseases, and autoimmunity. Currently, Anocca is focused on delivering T-cell receptor-modified T-cell therapies (TCR-T) in oncology. The company is rapidly progressing a pipeline of novel therapeutic TCR-T candidates generated entirely with their own technologies towards clinical trials, utilizing in-house state-of-the-art manufacturing capabilities and processes. The company recently received a substantial kr400.00M Venture Round investment on 31 May 2023 from a group of investors including Nidoco AB, Swedbank Robur, Swedish pension fund AMF, Michano AB, Mellby Gård AB, and Ramsbury Invest AB. Anocca is well-positioned to make significant strides in the biotechnology and healthcare industries with its innovative approach and cutting-edge technology, potentially addressing unmet patient needs in various therapeutic areas.